Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00575367 · ClinicalTrials.gov registry record · Phase 4
Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
A Phase 4 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT00575367 is a Phase 4 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 37 participants.
The verdict
NCT00575367, a Phase 4 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the drug concentrations of AzaSite compared to Vigamox in tears of healthy volunteers
Interventions
- DRUG AzaSite (azithromycin ophthalmic solution)
- DRUG Vigamox (moxifloxacin hydrochloride ophthalmic solution)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00575367
The ClinicalTrials.gov registry entry for NCT00575367 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AzaSite (azithromycin ophthalmic solution) is the first listed.
NCT00575367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00575367 about?
NCT00575367 is a clinical study titled "Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers". The purpose of this study is to evaluate the drug concentrations of AzaSite compared to Vigamox in tears of healthy volunteers
What is the current status of trial NCT00575367?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2008-03.
What interventions are being tested in trial NCT00575367?
The interventions under investigation include: AzaSite (azithromycin ophthalmic solution) (DRUG), Vigamox (moxifloxacin hydrochloride ophthalmic solution) (DRUG).
Who is sponsoring clinical trial NCT00575367?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.